REZUROCK (belumosudil) tablets, FDA Approved for Treatment of Chronic Graft-Versus-Host Disease, Available at Biologics by McKesson

July 30, 2021

CARY, N.C., July 30, 2021Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, today announced that it has been selected by Kadmon (Nasdaq: KDMN) as a specialty pharmacy provider for REZUROCK™ (belumosudil) for the treatment of adult and pediatric patients aged 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy.

REZUROCK, approved by the U.S. Food and Drug Administration (FDA) on July 16, 2021, is a selective oral inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), which is a signaling pathway that controls inflammatory and fibrotic responses. This treatment has previously been granted both Breakthrough Therapy and Orphan Drug designations by the FDA.

“Chronic graft-versus-host disease is one of the leading causes of medical complications after an allogeneic stem cell transplant,” said Ela Lourido, vice president of Biopharma Services at Biologics. “We’re honored to work with Kadmon to distribute this important new treatment option to patients.”

Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach. Each team includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients. This deeply skilled care team works together to develop individualized care plans that address each patient’s unique clinical, financial and emotional needs and streamlines communication back to the treating provider, enabling high-quality care and differentiated outcomes. In addition, the Biologics team works closely with payers to ensure patients can access the specialty medications they need.

Physicians may submit prescriptions to Biologics via phone (800.850.4306), fax (800.823.4506) or eScribe. For electronic prescribing systems, physicians may search for Biologics within their EMR system.

About Biologics by McKesson

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Built on the foundation of deep clinical expertise and a high-touch approach to patient care, Biologics delivers seamless access and personalized engagement, so patients get the most out of the care they receive. As a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.

Public Relations Contact